Cargando…

Increased circulating soluble urokinase-type plasminogen activator receptor (suPAR) levels in patients with slow coronary flow

INTRODUCTION: Slow coronary flow (SCF) is an angiographic phenomenon characterized by delayed opacification of epicardial coronary arteries without an obstructive coronary disease. Serum soluble urokinase-type plasminogen activator receptor (suPAR) levels seem closely related to atherosclerosis due...

Descripción completa

Detalles Bibliográficos
Autores principales: Emrah, Acar, Akın, İzgi İbrahim, Servet, İzci, Muzaffer, Kahyaoğlu, Fatih, Yılmaz Mehmet, Yeliz, Güler, Çağan, Efe Süleyman, Ahmet, Güler, Alev, Kılıçgedik, Cevat, Kırma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421532/
https://www.ncbi.nlm.nih.gov/pubmed/28905020
http://dx.doi.org/10.5114/amsad.2016.60819
_version_ 1783234603240128512
author Emrah, Acar
Akın, İzgi İbrahim
Servet, İzci
Muzaffer, Kahyaoğlu
Fatih, Yılmaz Mehmet
Yeliz, Güler
Çağan, Efe Süleyman
Ahmet, Güler
Alev, Kılıçgedik
Cevat, Kırma
author_facet Emrah, Acar
Akın, İzgi İbrahim
Servet, İzci
Muzaffer, Kahyaoğlu
Fatih, Yılmaz Mehmet
Yeliz, Güler
Çağan, Efe Süleyman
Ahmet, Güler
Alev, Kılıçgedik
Cevat, Kırma
author_sort Emrah, Acar
collection PubMed
description INTRODUCTION: Slow coronary flow (SCF) is an angiographic phenomenon characterized by delayed opacification of epicardial coronary arteries without an obstructive coronary disease. Serum soluble urokinase-type plasminogen activator receptor (suPAR) levels seem closely related to atherosclerosis due to increased inflammation and prothrombotic state. We studied whether circulating suPAR is related to SCF. MATERIAL AND METHODS: The present study was cross-sectional and observational. It included 75 individuals who underwent coronary angiography with suspected CAD and had angiographically normal coronary arteries of varying coronary flow rates. The relationship between suPAR, C-reactive protein (CRP) and SCF was investigated. Forty patients with isolated SCF (mean age: 46.0 ±4.14 years) and 35 age- and gender-matched control participants with normal coronary flow (NCF) and normal coronary arteries (NCA) (mean age: 46.0 ±5.7 years) were included in the study. We used logistic regression analysis to determine the predictors of SCF. RESULTS: The clinical characteristics were not statistically significantly different between SCF and NCA groups. Serum suPAR level was significantly higher in the SCF group than the control group (2.5–5.4 ng/ml vs. 0.1–1.4 ng/ml; p < 0.001). Also the serum CRP level was higher in the CSF group than the control group (1.57 ±0.43 mg/l vs. 0.53 ±0.23 mg/l; p < 0.001). CONCLUSIONS: This study revealed significantly increased serum suPAR levels in patients with SCF. Although we cannot draw conclusions on the underlying pathological process of SCF, we believe that these findings may be pioneering for further studies investigating the specific roles of circulating suPAR in the SCF phenomenon in the coronary vasculature.
format Online
Article
Text
id pubmed-5421532
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-54215322017-09-13 Increased circulating soluble urokinase-type plasminogen activator receptor (suPAR) levels in patients with slow coronary flow Emrah, Acar Akın, İzgi İbrahim Servet, İzci Muzaffer, Kahyaoğlu Fatih, Yılmaz Mehmet Yeliz, Güler Çağan, Efe Süleyman Ahmet, Güler Alev, Kılıçgedik Cevat, Kırma Arch Med Sci Atheroscler Dis Clinical Research INTRODUCTION: Slow coronary flow (SCF) is an angiographic phenomenon characterized by delayed opacification of epicardial coronary arteries without an obstructive coronary disease. Serum soluble urokinase-type plasminogen activator receptor (suPAR) levels seem closely related to atherosclerosis due to increased inflammation and prothrombotic state. We studied whether circulating suPAR is related to SCF. MATERIAL AND METHODS: The present study was cross-sectional and observational. It included 75 individuals who underwent coronary angiography with suspected CAD and had angiographically normal coronary arteries of varying coronary flow rates. The relationship between suPAR, C-reactive protein (CRP) and SCF was investigated. Forty patients with isolated SCF (mean age: 46.0 ±4.14 years) and 35 age- and gender-matched control participants with normal coronary flow (NCF) and normal coronary arteries (NCA) (mean age: 46.0 ±5.7 years) were included in the study. We used logistic regression analysis to determine the predictors of SCF. RESULTS: The clinical characteristics were not statistically significantly different between SCF and NCA groups. Serum suPAR level was significantly higher in the SCF group than the control group (2.5–5.4 ng/ml vs. 0.1–1.4 ng/ml; p < 0.001). Also the serum CRP level was higher in the CSF group than the control group (1.57 ±0.43 mg/l vs. 0.53 ±0.23 mg/l; p < 0.001). CONCLUSIONS: This study revealed significantly increased serum suPAR levels in patients with SCF. Although we cannot draw conclusions on the underlying pathological process of SCF, we believe that these findings may be pioneering for further studies investigating the specific roles of circulating suPAR in the SCF phenomenon in the coronary vasculature. Termedia Publishing House 2016-06-22 /pmc/articles/PMC5421532/ /pubmed/28905020 http://dx.doi.org/10.5114/amsad.2016.60819 Text en Copyright: © 2016 Termedia & Banach http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Clinical Research
Emrah, Acar
Akın, İzgi İbrahim
Servet, İzci
Muzaffer, Kahyaoğlu
Fatih, Yılmaz Mehmet
Yeliz, Güler
Çağan, Efe Süleyman
Ahmet, Güler
Alev, Kılıçgedik
Cevat, Kırma
Increased circulating soluble urokinase-type plasminogen activator receptor (suPAR) levels in patients with slow coronary flow
title Increased circulating soluble urokinase-type plasminogen activator receptor (suPAR) levels in patients with slow coronary flow
title_full Increased circulating soluble urokinase-type plasminogen activator receptor (suPAR) levels in patients with slow coronary flow
title_fullStr Increased circulating soluble urokinase-type plasminogen activator receptor (suPAR) levels in patients with slow coronary flow
title_full_unstemmed Increased circulating soluble urokinase-type plasminogen activator receptor (suPAR) levels in patients with slow coronary flow
title_short Increased circulating soluble urokinase-type plasminogen activator receptor (suPAR) levels in patients with slow coronary flow
title_sort increased circulating soluble urokinase-type plasminogen activator receptor (supar) levels in patients with slow coronary flow
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421532/
https://www.ncbi.nlm.nih.gov/pubmed/28905020
http://dx.doi.org/10.5114/amsad.2016.60819
work_keys_str_mv AT emrahacar increasedcirculatingsolubleurokinasetypeplasminogenactivatorreceptorsuparlevelsinpatientswithslowcoronaryflow
AT akınizgiibrahim increasedcirculatingsolubleurokinasetypeplasminogenactivatorreceptorsuparlevelsinpatientswithslowcoronaryflow
AT servetizci increasedcirculatingsolubleurokinasetypeplasminogenactivatorreceptorsuparlevelsinpatientswithslowcoronaryflow
AT muzafferkahyaoglu increasedcirculatingsolubleurokinasetypeplasminogenactivatorreceptorsuparlevelsinpatientswithslowcoronaryflow
AT fatihyılmazmehmet increasedcirculatingsolubleurokinasetypeplasminogenactivatorreceptorsuparlevelsinpatientswithslowcoronaryflow
AT yelizguler increasedcirculatingsolubleurokinasetypeplasminogenactivatorreceptorsuparlevelsinpatientswithslowcoronaryflow
AT caganefesuleyman increasedcirculatingsolubleurokinasetypeplasminogenactivatorreceptorsuparlevelsinpatientswithslowcoronaryflow
AT ahmetguler increasedcirculatingsolubleurokinasetypeplasminogenactivatorreceptorsuparlevelsinpatientswithslowcoronaryflow
AT alevkılıcgedik increasedcirculatingsolubleurokinasetypeplasminogenactivatorreceptorsuparlevelsinpatientswithslowcoronaryflow
AT cevatkırma increasedcirculatingsolubleurokinasetypeplasminogenactivatorreceptorsuparlevelsinpatientswithslowcoronaryflow